DOI: https://doi.org/10.22263/2312-4156.2017.3.63
Kotau A.A.
Short-term results of adjuvant chemoradiotherapy for locally advanced gastric cancer
N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus
Vestnik VGMU. 2017;16(3):63-72.
Abstract.
Objectives. To improve the treatment results of patients with locally advanced gastric cancer by means of employing adjuvant chemoradiotherapy aimed at reducing the incidence of locoregional recurrences and distant metastases.
Material and methods. A prospective randomized study evaluated the short-term treatment results of patients after radical surgery with D2 lymph node dissection for locally advanced gastric cancer. One hundred and twenty-one patients were randomly assigned to the adjuvant therapy group. Their treatment starting in 4-6 weeks after surgery included external-beam hypofractionated 3D-conformal radiation therapy (STD 4 Gy 5 days a week, TTD 32 Gy, equivalent TTD 46 Gy) and oral tegafur monochemotherapy 10-15 mg/kg daily for 5 months. The radiation volume included the tumor bed, regional metastatic lymphogenous spread areas and, in case of tumor invasion of the upper third of gastric visceral peritoneum, the left dome of the diaphragm.
Results. No grade IV treatment toxicity and treatment-related deaths were observed. All the patients received the complete course of radiotherapy within the time scheduled, grade III toxicity was leukopenia in 4,1%. The rates of grade III side effects of monochemotherapy were as follows: nausea and vomiting – 4,5%, leukopenia – 3,6%. Untimely termination of monochemotherapy occurred in 36,9% of patients, including 14,4% because of treatment toxicity. Grade II radiation enteropathy rate was in 8,1% of patients, no grade III-IV late toxicity was observed.
Conclusions. The elaborated technique for multimodality gastric cancer treatment is characterized by satisfactory tolerance and may be subject for further study.
Key words: locally advanced gastric cancer, adjuvant chemoradiotherapy, hypofractionation, radiation enteropathy.
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: http://dx.doi.org/10.3322/caac.21262
2. Okeanov AE, Moiseev PI, Levin LF. Statistics of oncologic diseases. Minsk, RB: RNPTs OMR; 2016. 279 р. (In Russ.)
3. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi57-63. doi: http://dx.doi.org/10.1093/annonc/mdt344
4. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011 Jun;14(2):113-23. doi: http://dx.doi.org/10.1007/s10120-011-0042-4
5. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Oct;14(10):1286-1312.
6. Gunderson LL, Sosin H. Andenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic looks) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):1-11.
7. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449-61.
8. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep;345(10):725-30. doi: http://dx.doi.org/10.1056/NEJMoa010187
9. Linares I, Tovar MI, Zurita M, Guerrero R, Expósito M, Del Moral R. Hypofractionated breast radiation: shorter scheme, lower toxicity. Clin Breast Cancer. 2016 Aug;16(4):262-8. doi: http://dx.doi.org/10.1016/j.clbc.2015.09.012
10. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul;26(21):3496-502. doi: http://dx.doi.org/10.1200/JCO.2007.15.8634
11. Garajová I, Di Girolamo S, de Rosa F, Corbelli J, Agostini V, Biasco G, et al. Neoadjuvant treatment in rectal cancer: actual status. Chemother Res Pract. 2011;2011:839742. doi: http://dx.doi.org/10.1155/2011/839742
12. Bjerkeset T, Fjøsne HE. Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon, or rectum. Oncology. 1986;43(4):212-5.
13. Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother. 2006 Jun;18(3):311-7. doi: http://dx.doi.org/10.1179/joc.2006.18.3.311
14. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov;357(18):1810-20. doi: http://dx.doi.org/10.1056/NEJMoa072252
15. Japanese Gastric Cancer Association. Japanese Classification of Gastric Cancer – 2nd English Edition. Gastric Cancer. 1998 Dec;1(1):10-24. doi: http://dx.doi.org/10.1007/s101209800016
16. National Cancer Institute. Common Terminology Criteria for Adverse Events – CTCAE v5.0 Draft 1 [Electronic resource]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAEv5.xlsx.
17. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995 Mar;31(5):1341-6. doi: http://dx.doi.org/10.1016/0360-3016(95)00060-C
18. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm – general principles. Nat Clin Pract Oncol. 2007 Feb;4(2):86-100. doi: http://dx.doi.org/10.1038/ncponc0714
19. Gladilina IA. A radiosensibilization in radiation therapy of malignant neoplasms. Effektiv Farmakoterapiia. 2011;(22):46-53. (In Russ.)
20. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999 Oct;5(10):2948-53.
21. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetic of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002 Feb;38(3):349-58.
22. Diaz-Nieto R, Orti-Rodríguez R, Winslet M. Diaz-Nieto, R. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013 Sep;(9):CD008415. doi: http://dx.doi.org/10.1002/14651858.CD008415
23. Cao J, Qi F, Liu T. Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis. Scand J Gastroenterol. 2014 Jun;49(6):690-704. doi: http://dx.doi.org/10.3109/00365521.2014.907337
24. Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncol. 1987;26(6):433-6.
25. Lim DH, Kim DY, Kang MK, KimYI, KangWK, Park CK, et al. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist’s view. Br J Cancer. 2004 Jul;91(1):11-7. doi: http://dx.doi.org/10.1038/sj.bjc.6601896
26. Gemici C, Sargin M, Uygur-Bayramicli O, Mayadagli A, Yaprak G, Dabak R, et al. Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer. Radiotelegraph Oncol. 2013 May;107(2):195-9. doi: http://dx.doi.org/10.1016/j.radonc.2013.04.013
27. Wydmanski J, Polanowski P, Tukiendorf A, Maslyk B. Radiation-induced injury of the exocrine pancreas after chemoradiotherapy for gastric cancer. Radiother Oncol. 2016 Mar;118(3):535-9. doi: http://dx.doi.org/10.1016/j.radonc.2015.11.033
28. Yeoh E, Horowitz M, Russo A, Muecke T, Robb T, Maddox A, et al. Effect of pelvic irradiation on gastrointestinal function: a prospective longitudinal study. Am J Med. 1993 Oct;95(4):397-406.
29. Classen J, Belka C, Paulsen F, Budach W, Hoffmann W, Bamberg M. Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Strahlenther Onkol. 1998 Nov;174 Suppl 3:82-4.
30. Ferreira MR, Muls A, Dearnaley DP,Andreyev HJ. Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist. Lancet Oncol. 2014 Mar;15(3):e139-47. doi: http://dx.doi.org/10.1016/S1470-2045(13)70504-7
31. Barney BM, Markovic SN, Laack NN, Miller RC, Sarkaria JN, Macdonald OK, et al. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys. 2013 Sep;87(1):73-80. doi: http://dx.doi.org/10.1016/j.ijrobp.2013.05.012
32. Letschert JG, Lebesque JV, de Boer RW, Hart AA, Bartelink H. Dose-volume correlation in radiation-related late small-bowel complications: a clinical study. Radiother Oncol. 1990 Aug;18(4):307-20.
33. Miller AR, Martenson JA, Nelson H, Schleck CD, Ilstrup DM, Gunderson LL, et al. The incidence and clinical consequences of treatment-related bowel injury. Int J Radiat Oncol Biol Phys. 1999 Mar;43(4):817-25.
34. Kasibhatla M, Clough RW, Montana GS, Oleson JR, Light K, Steffey BA, Jones EL. Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2006 Mar;65(2):398-403. doi: http://dx.doi.org/10.1016/j.ijrobp.2005.12.008
35. Hauer-Jensen M. Late radiation injury of the small intestine. Clinical, pathophysiologic and radiobiologic aspects. A review. Acta Oncol. 1990;29(4):401-15.
36. Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach M, et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys. 1999 May;44(2):327-31.
37. Rakovitch E, Fyles AW, Pintilie M, Leung PM. Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1997 Jul;38(5):979-87.
38. Shmak AI, Sukolinskiy VN. The combined treatment of patients with cancer of a stomach with use of intensive regimens of preoperative radiation therapy. Biul Sibir Meditsiny. 2005;4(1):60-3. (In Russ.)
39. Yeoh EK, Horowitz M, Russo A, Muecke T, Robb T, Chatterton BE. Gastrointestinal function in chronic radiation enteritis – effects of loperamide-N-oxide. Gut. 1993 Apr;34(4):476-82.
40. Libotte F, Autier P, Delmelle M, Gozy M, Pector JC, Van Houtte P, et al. Survival of patients with radiation enteritis of the small and the large intestine. Acta Chir Belg. 1995;95(4 Suppl):190-4.
Information about authors:
Kotau A.A. – head of the oncology department of hepatopancreatobiliary pathology, abdominal oncopathhology division, N.N. Alexandrov National Cancer Center of Belarus.
Correspondence address: Republic of Belarus, 223040, Minsk district, agrogorodok Lesnoy, N.N. Alexandrov National Cancer Centre of Belarus, abdominal oncopathhology division, oncology department of hepatopancreatobiliary pathology. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Anatoly A. Kotau.
